tiprankstipranks
Palatin reports preliminary Q2 Vyleesi sales up 15.4% sequentially
The Fly

Palatin reports preliminary Q2 Vyleesi sales up 15.4% sequentially

Palatin Technologies reported preliminary Q2 Vyleesi product sales results. Vyleesi is the first and only as-needed treatment approved by the FDA for premenopausal women with acquired, generalized hypoactive sexual desire disorder – HSDD -. Q2 product revenue of $1.0M exceeded Vyleesi operating expenses. Gross product sales were $2.6M, up 14.1% over the prior quarter and 238% over the comparable quarter in 2021. Net product revenue was $1.0M, an increase of 15.4% over the prior quarter, and an increase of 1,290% over the comparable quarter in 2021. Total prescriptions dispensed increased 11.5% over the prior quarter and increased 134% over the comparable quarter in 2021. Refill rates, commercial insurance reimbursement, and net revenue per prescription dispensed, increased over the prior quarter and comparable quarter in 2021.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on PTN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles